according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

SECTION 1. IDENTIFICATION

Product name : Imipenem / Cilastatin Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Eye irritation : Category 2A

Respiratory sensitization : Sub-category 1A

Reproductive toxicity : Category 2

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H319 Causes serious eye irritation.

H334 May cause allergy or asthma symptoms or breathing diffi-

culties if inhaled.

H361d Suspected of damaging the unborn child.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P261 Avoid breathing dust.

P264 Wash skin thoroughly after handling.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

P284 Wear respiratory protection.

Response:

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0 P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical attention. P337 + P313 If eye irritation persists: Get medical attention. P342 + P311 If experiencing respiratory symptoms: Call a doc-Storage: P405 Store locked up.

Other hazards

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Disposal:

disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cilastatin	No data availa- ble	81129-83-1	>= 30 - < 60 *
Imipenem	No data availa- ble	74431-23-5	>= 30 - < 60 *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

P501 Dispose of contents and container to an approved waste

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis,

reactive airways dysfunction syndrome).

Contact with dust can cause mechanical irritation or drying of

the skin.

Causes serious eye irritation.

May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

Suspected of damaging the unborn child.

First Aid responders should pay attention to self-protection. Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation Advice on safe handling

Do not breathe dust.

Do not swallow.

Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labeled containers. Conditions for safe storage

Store locked up.

Keep tightly closed.

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis			
		exposure)	concentration				
Cilastatin	81129-83-1	TWA	5 mg/m3 (OEB 1)	Internal			
Imipenem	74431-23-5	TWA	3000 ug/m3 (OEB	Internal			
			1)				
	Further inform	Further information: RSEN, DSEN					
		Wipe limit	100 μg/100 cm2	Internal			

Engineering measures Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

> exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Particulates type

Filter type Hand protection

Material Chemical-resistant gloves

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat.

Hygiene measures If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance powder

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Color : white

Odor : sulfurous

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : 1 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0

Molecular weight No data available

Particle characteristics

Particle size No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Stable under normal conditions. Chemical stability

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cilastatin:

Acute oral toxicity LD50 (Rat): 8,000 mg/kg

LD50 (Mouse): 8,000 mg/kg

Imipenem:

Acute oral toxicity LD50 (Mouse): 10,000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous

LD50 (Mouse): 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Components:

Cilastatin:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Cilastatin:

Species : Rabbit

Result : Moderate eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cilastatin:

Routes of exposure : Skin contact
Remarks : No data available

Routes of exposure : Inhalation

Remarks : No data available

Imipenem:

Remarks : May cause sensitization of susceptible persons by inhalation

of aerosol or dust.

Routes of exposure : Skin contact

Remarks : Not classified due to lack of data.

Germ cell mutagenicity

Not classified based on available information.

Components:

Cilastatin:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

Result: negative

Imipenem:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Test Type: reverse mutation assay

Result: negative

Test Type: unscheduled DNA synthesis assay

Result: negative

Test Type: Chromosomal aberration

Result: negative

Test Type: sister chromatid exchange assay

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intravenous

Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cilastatin:

Effects on fertility : Test Type: Fertility/early embryonic development

Application Route: Intravenous

Fertility: LOAEL: 1,000

Symptoms: No adverse effects.

Result: No effects on fertility and early embryonic

development were detected.

Imipenem:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male and female Application Route: Intravenous

Fertility: LOAEL: 80 mg/kg body weight

Symptoms: No adverse effects., Reduced fetal weight. Result: No effects on fertility and early embryonic

development were detected.

Test Type: Fertility/early embryonic development

Species: Rat, male and female Application Route: Subcutaneous Fertility: LOAEL: 320 mg/kg body weight

Symptoms: No adverse effects., Reduced fetal weight. Result: No effects on fertility and early embryonic

development were detected.

Effects on fetal development : Test Type: Development

Species: Monkey

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Application Route: Intravenous

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development

Species: Rabbit

Application Route: Intravenous

Developmental Toxicity: NOAEL: 60 mg/kg body weight

Result: No teratogenic effects.

Test Type: Development

Species: Rat

Application Route: Intravenous

Developmental Toxicity: NOAEL: 60 mg/kg body weight

Result: No teratogenic effects.

Reproductive toxicity - As-

sessment

: Some evidence of adverse effects on development, based on

animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Cilastatin:

Species : Rat

NOAEL : >= 500 mg/kg
Application Route : Intravenous
Exposure time : 90 Days

Remarks : No significant adverse effects were reported

Species : Monkey

NOAEL : >= 500 mg/kg

Application Route : Intravenous

Exposure time : 5 Weeks

Remarks : No significant adverse effects were reported

Imipenem:

Species: MonkeyNOAEL: 60 mg/kgLOAEL: 150 mg/kgApplication Route: IntravenousExposure time: 6 MonthsTarget Organs: Kidney

Species : Monkey NOAEL : 120 mg/kg

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0

Application Route Subcutaneous Exposure time 6 Months

Remarks No significant adverse effects were reported

Species Rat NOAEL 180 mg/kg Application Route Intravenous Exposure time 6 Months

Remarks No significant adverse effects were reported

Species Rabbit LOAEL 150 mg/kg Application Route Intravenous Target Organs Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Imipenem:

Inhalation Symptoms: Nausea, Vomiting, Diarrhea, Fever, hypotension,

Dizziness, Drowsiness, Convulsions, pruritis, Rash

Remarks: May cause sensitization of susceptible persons by

inhalation of aerosol or dust.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cilastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 99 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: EC50 (Anabaena flos-aquae): > 99 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 99

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 99 mg/l

Exposure time: 72 h

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 99

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

EC10 (Pimephales promelas (fathead minnow)): > 9.9 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

EC10 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Imipenem:

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 78 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 74

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 74

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.4 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 11 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms

EC50: > 1,000 mg/l Exposure time: 3 h

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

> Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cilastatin:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 27 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Imipenem:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 29 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Cilastatin:

Partition coefficient: n-

octanol/water

log Pow: -3.53

Imipenem:

Partition coefficient: n-

octanol/water

: log Pow: < -1

Mobility in soil

Components:

Cilastatin:

Distribution among environ: log Koc: 2.3

mental compartments

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Empty containers should be taken to an approved waste Contaminated packaging

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/14/2025 06/17/2025 15817-00032 Date of first issue: 11/05/2014 8.0

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN 3077 UN number

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Imipenem)

9 Class Packing group Ш Labels 9 Environmentally hazardous yes

IATA-DGR

UN/ID No. UN 3077

Proper shipping name Environmentally hazardous substance, solid, n.o.s.

(Imipenem)

9 Class Packing group Ш

Labels Miscellaneous

Packing instruction (cargo 956

aircraft)

Packing instruction (passen-

ger aircraft)

956

Environmentally hazardous

yes

IMDG-Code

UN number **UN 3077**

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Imipenem)

Class 9 Ш Packing group Labels 9 **EmS Code** F-A, S-F Marine pollutant ves

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number **UN 3077**

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Imipenem)

9 Class Packing group Ш Labels 9 **ERG Code** 171

yes(Imipenem) Marine pollutant

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

according to the Hazardous Products Regulations



Imipenem / Cilastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/14/2025 8.0 06/17/2025 15817-00032 Date of first issue: 11/05/2014

Sources of key data used to

compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 06/17/2025 Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8